PMID- 15197496
OWN - NLM
STAT- MEDLINE
DCOM- 20041124
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 53
IP  - 11
DP  - 2004 Nov
TI  - Dendritic cells in colorectal cancer correlate with other tumor-infiltrating 
      immune cells.
PG  - 978-86
AB  - Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a 
      key role in a cellular antitumor immune response. In this study we investigated 
      the exact localization of DCs within colorectal tumors and their relationship to 
      tumor-infiltrating lymphocytes as well as clinical outcome of the patients. 
      Primary tumor specimens of 104 patients with a diagnosis of colorectal cancer 
      were identified retrospectively and analyzed with the dendritic cell markers 
      S-100 protein and human leukocyte antigens (HLA) class II. The markers were 
      individually combined with laminin as a second marker to facilitate the 
      observation of the different tumor localizations. S-100 or HLA class II positive 
      cells were found in the three different compartments of colorectal tumors: tumor 
      epithelium, tumor stroma, and advancing tumor margin, but mainly present in tumor 
      stroma and advancing tumor margin. S-100-positive tumor-infiltrating DCs in 
      direct contact with tumor cells, i.e., in tumor epithelium, significantly 
      correlated to the intraepithelial infiltration of CD4+ (p=0.02) and CD8+ (p=0.01) 
      lymphocytes. High HLA class II+ cell infiltration in the tumor stroma correlated 
      to a lower intraepithelial infiltration of CD8+ (p=0.02) lymphocytes. High 
      intraepithelial infiltration of S-100-positive DCs suggested increased 
      disease-free survival, but was not statistically significant, while high amounts 
      of HLA class II+ cells in the tumor stroma correlated with an adverse survival 
      outcome. Our results show that the infiltration of DCs in colorectal cancer, 
      depending on both location and type of marker, is correlated with local immune 
      interactions and patient prognosis, suggesting a central role for DCs in 
      controlling local tumor immunity.
FAU - Dadabayev, A R
AU  - Dadabayev AR
AD  - Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC, 
      Leiden, The Netherlands.
FAU - Sandel, M H
AU  - Sandel MH
FAU - Menon, A G
AU  - Menon AG
FAU - Morreau, H
AU  - Morreau H
FAU - Melief, C J M
AU  - Melief CJ
FAU - Offringa, R
AU  - Offringa R
FAU - van der Burg, S H
AU  - van der Burg SH
FAU - Janssen-van Rhijn, C
AU  - Janssen-van Rhijn C
FAU - Ensink, N G
AU  - Ensink NG
FAU - Tollenaar, R A E M
AU  - Tollenaar RA
FAU - van de Velde, C J H
AU  - van de Velde CJ
FAU - Kuppen, P J K
AU  - Kuppen PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040617
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Laminin)
RN  - 0 (S100 Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigen-Presenting Cells/metabolism
MH  - CD4-Positive T-Lymphocytes/immunology/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*immunology/*metabolism
MH  - Dendritic Cells/*cytology/immunology/metabolism
MH  - Disease-Free Survival
MH  - Epithelium/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Histocompatibility Antigens Class II/*chemistry
MH  - Humans
MH  - Immunohistochemistry
MH  - Laminin/chemistry
MH  - Lymphocytes/metabolism
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - S100 Proteins/*biosynthesis/chemistry
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC11042674
EDAT- 2004/06/16 05:00
MHDA- 2004/12/16 09:00
PMCR- 2004/06/17
CRDT- 2004/06/16 05:00
PHST- 2003/12/15 00:00 [received]
PHST- 2004/04/06 00:00 [accepted]
PHST- 2004/06/16 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/06/16 05:00 [entrez]
PHST- 2004/06/17 00:00 [pmc-release]
AID - 548 [pii]
AID - 10.1007/s00262-004-0548-2 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2004 Nov;53(11):978-86. doi: 
      10.1007/s00262-004-0548-2. Epub 2004 Jun 17.